reduced by the raised intrathoracic pressure caused by the convulsion and by intermittent positive pressure ventilation (1PPV). Other physiological changes may relate to muscular work and anoxia.
The autonomic disturbance consists of a parasympathetic-synapathetic sequence during the early pan of the procedure, followed by a similar but tess marked sequence, starting in the r phase of the seizure and persisting into recovery. Parasympathetic discharge occurs immediately the current is applied, and the first sympathetic surge follows within seconds. The second sequence is lcss rapid and less severe.
These changes were investigated in dogs by Anton. 7 During a five-second shock the dog was asystolic, with a dramatic fall in blood pressure (Figure) . Immediately following the shock, cardiac rhythm returned, and the animal exhibited bradycardia and hypertension. The initial asystole could be abolished by atropine or the ganglion-blocker ecolid. The post-shock rise in blood pressure could be reduced by alpha-adrenergic blockade, using phenoxybenzamine or high spinal block.
The same study showed a rise in circulating catecholamines. This also occurs in man, s and is reduced by anaesthesia. 9 Sympathetic-induced dysrhythmias and hypertension after treatment may occasionally be severe. In some patients the blood pressure reaches a peak within 60 seconds and then returns to normal, although in some it continues to rise for three minutes.~~ Patients with untreated essential hypertension do not show a greater hypertensive response. I~ Severe hypertension following ECT should be controlled with beta-adrenergic blockers, and pro- pranolol is effective, tz It may be given prior to treatment. 13 Although propranolol may exaggerate the muscarinic effects of suecinylcholine, v~ it gives better control than nitroprusside or diazonide, which cause persistent hypotension. ~5, 16 Monitoring the heart rate and blood pressure regularly during treatment and recovery is therefore mandatory. Readily available facilities and expertise for performing cardiopulmonary resuscitation are essential.
Modification by anaesthetic drugs

Anticholinergics
Atropine has been routinely administered before ECT to attenuate excess vagal stimulation of the heart. It may be given subcutaneously an hour before treatment or intravenously immediately before induction. The intravenous route is more cffective in preventing bradycardia, and spares the patient the discomfort of a dry mouth 17 _ it is widely used. 3, 4 This current routine is now being questioned. French m argues that most patients have a tachycardia preceding treatment, possibly due to tricyclic antidepressant therapy, and that if bradycardia or asystole occurs this reflects inadequate ventilation.
Succinylcholine may cause a bradycardia, but pretreatment with atropine does not offer significant protection. 19 The practical benefits of intravenous atropine appeared small in two published series. Wyant ~~ performed a within-patient crossover trial, on 37 patients. He gave 1.0 mg or 0.5 rag, or none, ten seconds or two minutes belbre induction. Tachycardia occurred in all groups before treatment, and intravenous atropine conferred no particular benefit or protection. In particular, the antisialogoguc effects were not clinically beneficial.
Verheeke 22 confirms this contention. In a series of 6000 ECT's, over a period of 24 years, he claims severe bradycardia (50 beats per minute) was not detected clinically, and sialorrhoea was not troublesome.
A well-publicised death after ECT was blamed on inadequate atropinisation. 23 However, cardiorespiratory arrest occurred ten minutes after the shock. No ECG recordings were available at the time, and the initial rapid response to resuscitation suggests hypoventilation may have been responsible.
On the basis of the available evidence, the routine administration of atropine does not seem necessary. It should, however, be readily available whenever ECT is performed.
Induction agents
Anaesthetic requirements include smooth induc~ tion, autonomic stability, safety with repeated administration and rapid recovery. The recovery period is significantly affected by the patient's concomitant psychotropic medication, For the past twenty years, methohexitone has been the most popular anaesthetic agent. 24 After a series of within-patient crossover trials, Allen and co-workers ~ showed it to be the drug of choice, and it remains the most widely used. 3 Thiopentone, another barbiturate, has also been used. However, it offers no significant advantages over methohexitone and may prolong the recovery time 26. 28 Propranidid, a eugenol derivative, provides rapid recovery, 29,3~ but prolongs the action of succinylcholine. 3~ It has a high incidence of anaphylactoid reactions. 3e However. it is widely used in RussiaY Alfathesin (alfadolone/alfaxolone) also provides fast recovery, though slower than methohexitone 3,~ with no prolongation of the apnoea time. However, the incidence of anaphylactie reactions, particularly on repeated administration, 35 led to its withdrawal by the manufacturers in 1984.
Ketamine was claimed to be a safer drug 36 with little evidence. It has sympathomimetic properties which are undesirable~ recovery is slower than after methohexitone, and there is a high incidence ef nausea and ataxia. ~? Emergence hallucinations are rare, dueeither to some aspect of the treatment or to concomitant medication. Intramuscular ketamine may rarely be justified if intravenous access is impossible.
Etomidate was studied in an uncontrolled trial 38 and the authors expressed some enthusiasm, although noting the high incidence of pain on injection. A more objective trial 39 found recovery was no faster than after Alfathesin, and induction was more stormy
The incidence of post-treatment anxiety, agitation, headaches and giddiness may be reduced by pretreatment with intravenous diazepam or haloperidol. Although neither drug prolongs the recovery period, 4~ there is evidence that administration of benzodiazepines shortens seizure duration, 27 and should not be routinely given.
Methohexitone remains the drug of choice for most patients undergoing ECT. Other drugs offer little advantage in the majority of patients.
Muscle relaxants
The violence of the convulsions led to the use of muscle relaxants during ECT, proceeding their use in anaesthesia. Curare was the first used by Bennett, 4~ but succinylcholine is now the most popular.
When neuromuscular blockers are used, it may be difficult for the therapist to ascertain whether a convulsion has actually occurred. Dilatation of the pupils, "goose-flesh," flickering of the eyelids or jerking of the toes have been used as signs of cerebral seizure. These are not dependable, "~6 as they can result from direct stimulation of peripheral pathways.
The surest way to record a seizure is electroencephalography, and some modern ECT instruments include a recorder for the direct measurement of EEG activity. An alternative method is to inflate a tourniquet around an arm, above arterial pressure, before giving the relaxant. This "isolated forearm" will then exhibit the tonic and clonie phases. When unilateral ECT is given, the cuff should be placed on the homolateral arm. Arm movements persisting for 25 seconds or more is regarded as adequate evidence that a convulsion has occurred -this correlates well with EEG recordings "2 and is an acceptable alternative.
Muscle relaxants have reduced but not abolished traumatic complications. During application of the current, the jaws clench, and tooth damage resulting from force on a Guedel airway has occurred. 4~ To prevent this, a rubber or plastic "bite block" should be inserted prior to stimulation. Other reported injuries include spontaneous rupture of the spleen.'~4
There is a period of apnoea lasting about two minutes after the shock, during which artificial ventilation is performed with oxygen. Joshi's claim that this is unnecessary 45 seems extremely dangerous -90 seconds of apnoea without preoxygenation results in a substantial fall in arterial PQ to a level which threatens the subject with loss of consciousnessJ 6
Succinyleholine dosage should be carefully judged. Pitts 47 found that 0.3 mg-kg -t gave little modification (softening of convulsions), 0.4 mg'kg-i reduced the number of vigorous seizures and 0.5 mg'kg -~ prevented them. 0.6 mg.kg ' caused a prolonged period of apnoea, and he concluded 0.5 mg.kg i was the optimal dose. The dose given and the clinical effects should bc recorded after each administration, and subsequent doses adjusted accordingly.
The duration of apnoea after a given dose of succinylcholine is reduced by ECT. 48 It is prolonged by lithium, although this interaction is probably not clinically significant. 49'5~ It is fortunate that muscle pains are remarkably uncommon after succinylchofine administration for ECT. 26'29'5~ This is in spite of the fact that these patients are ambulant and show normal fasciculations.
Contraindlcations to succinylcholine are rare, though in some patients, it must be considered an 32 unacceptable drug. Allergy is not uncommon, and these patiems should be given an alternative relaxant. Succinylcholine is also undesirable in patients with cholinesterase deficiency -the most extreme case being homozygotes for atypical gencs who may only require 1-3 mg. s2 This dose would be too low for heterozygotes or patients with acquired cholinesterase deficiency.
Suceinylcholine may also produce an unwanted rise in serum potassium. 4~'53 As an alternative, gallamine (80 mg) has been advocated by Brunton, who reported the duration of apnoea post-shock (using neostigmine reversal) was only one rain-ute. e'* The role of the newer short-acting nondepolarising relaxants remains to be seen.
Whenever neuromuscular blockers are used, there is a risk that the patient may be aware whilst paralysed. This may occur if succinylcholine is given together with propranidid 262~ or monoamine oxidase inhibitors (see below) or to patients with abnormal pseudocholinesterase. Although the Orthopaedic amnesia induced by ECT may prevent the patient from recalling this experience, this is not always P~lmonary reliable, ss and such patients are unlikely to consent Neurological tO a further treatment.
Other Assessment of patients
All patients subjected to ECT should undergo a thorough physical examination, and a detailed medical history should be taken, s6 Particular attention should be paid to cardiorespiratory function, symptoms of oesophageal retlux, allergies, and previous anaesthetic experience, and a full neurological assessment should be made. The presence of loose or missing teeth should be recorded. Suggested minimum investigations are given in Table 1 . The patient should give written consent to the procedure. Records should be kept of each administration. This should include details of the drugs given and their effects, the nature of the convulsion, the heart rate and blood pressure during the treatment and subsequent 60 minutes and any side effects or complications encountered.
Contraindieations and precautions (see Table It ) Myocardial infarction within the preceding three months constitutes an absolute contraindication, although at least one patient has inadvertently undergone ECT whilst during the acute phase. 57 Remediable conditions, e.g., thyrotoxicosis, pernicious anemia, pregnancy.
The presence of severe ischaemic heart disease is also a contraindication, in view of the possible cardiovascular stress imposed by ECT (see above).
Patients with cardiac pacemakers present little problem since, providing the pacemaker is correctly sited, virtually no current passes the heart. During the convulsion, skeletal muscle potentials may fall within the range of the pacemaker's sensing circuits, and inhibit demand pacemakers. The magnetoperated switch, fitted in most devices, should then be activated. The patient should be isolated from ground, and the electrocardiogram should be monitored during and after treatment, sS's9
Cerebral tumours, particularly when associated with raised intracranial pressure, are usually considered a contraindication to ECT. Maltbie 6~ reports a 28 per cent one-month mortality in these patients, although Dressier m considers it justifiable in depression associated with terminal disseminated malignancy. A rise in cerebral blood flow, lasting for some hours, occurs after ECT, 62 which may be responsible for a further rise in intracranial pressure.
Thrombophlebitis was originally considered a eontraindication because of the risk of dislodging an embolus-nowadays these patients would be treated with anticoagulants. Although there are risks from intracranial bleeding after ECT, there have been no reported cases in anticoagulated patients, and Alexopolous et al. 63 report two uneventful cases. They suggest that warfarin is changed to heparin before a course of treatment, to allow better control, and reduce the possibility of drug interactions.
ECT causes significant elevation of intraocular pressure after the convulsion, 64 which may be undesirable in patients wi~h glaucoma. Malignant hyperpyrexia, cornlnonly precipitated by succinylcholine, has not been reported after ECT in the past 16 years, e5 It is unlikely that this would have been undetected -perhaps the short exposure terminates attacks. A patient with a history of malignant hyperpyrexia has been successfully managed by Franks, 66 using pretreatment with dantrolene, premedication with diazepam, meperidine and droperidol, and induction with thiamylal without a relaxant.
Operators of ECT equipment have received electric shocks. The electrolyte solution, uscd to ensure good electrical contact between electrode and patient, may drip along the legs of the hcadset, producing a conducting path. The operator usually holds the headset in one hand and supports the chin with the other, and is at risk of electrocution. It is wise practice to wear rubber gloves, and to minimise the amount of electrolyte used. 67
Antidepressant therapy
Antidepressant therapy may cause cardiovascular disturbances. However, depressive illness itself is associated with an autonomic disturbance, characterised by a decrease in central sympathetic outflow, coupled with increases in alpha-adrenergic and decreases in beta activity. This profile varies with the severity of the depression. 6s The anticholinergic side effects complained of during antidepressant therapy may be a feature of the disease rather than the drug. 69'7~ Antidepressant drugs commonly used include tricyclics and monoamine oxidase inhibitors. Tricyclics, as a group, are all similar although some are more sedative than others. Cardiotoxicity may occur in therapeutic doses, causing tachycardia and conduction abnormalities, and they enhance the action of epinephrine and norepinephrine. Mianserin, a tetracyclic, is relatively free of these effects. 7~
Monoamine oxidase inhibitors (MAOI's) have great potential toxicity, and there is a tendency to employ them only in cases which fail to respond to other drugs or ECT. They form a stable complex with the enzyme, and regeneration of new enzyme takes 10-14 days.
Postural hypotension and an exaggerated hypotensive response to anaesthetic agents are common. In addition, hypertensive crises can occur if patients who have taken these drugs are exposed to ccrtain foods or drugs. A number of therapeutic agents not metabolised by monoamine oxidase are potentiated, especially sympathomimetic anrines. 72 '73 These pressor eftects are patti cularly common with pargyline and iproniazid.
Cardiac arrest has occurred after both modified and unmodified ECT in patients taking these drugs, probably due to uncontrolled sympalhetic activity. 74 Such a crisis may be managed with alphaadrcnergic blockers.
In addition, phenelzine may (reversibly) reduce serum pseudocholinesterase activity, and patients taking it have remained paralysed for up to an hour after a dose of succinylcholine. 7~
ECT in patients taking MAOI's presents considerable risks, and most psychiatrists agmc should not be performed. :~
Mortality
It is noteworthy that the mortality amongst depressed patients is increased compared to the age-corrected population, even excluding deaths from suicide. Those having ECT have the lowest mortality. 76 In the 19a0's, the mortality of ECT was 13,06 per cent, and in the five years up to 1953.67 deaths occurred in Britain. This compared favourably with leucotomy but was higher than after insulin therapy. The majority of these deaths were related to the cardiovascular system, although only two were due to primary cardiac arrest. Nineteen related to the respiratory system, including thrce cases of pulmonary emboIus. At least two were caused by anaesthesia. 77 Recently, a series was reported in which one death occurred in 42 patients. 5 In another American series, three deaths were recorded in 1,765 patients, 4 while a series from Britain quotes tour deaths in 2,594 patients 3 and an Australian series 26 reports no deaths in 3,500 administrations. The overall mortality in these series is 0.16 per cent, but it is unclear why there is such large variation between hospitals.
The risks of ECT have to be balanced against the toxicity of antidepressants -many consider that ECT is the safest and most effective treatment for severe depression. This particularly applies Ln elderly patients, 78 in whom ECT is particularly widely used. 3
